Inhibikase Therapeutics Inc (IKT)

Inhibikase Therapeutics Inc (IKT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $251M; returns 1 day -2.5%, 1 week -3.6%, 1 year +3.9%.

Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company focused on developing novel therapeutics, primarily centered around its lead product candidate, IKT-001.

Groups IKT belongs to

• Clinical Stage Biotech
• Biotechnology
• Pharmaceuticals
• Healthcare
• Biopharmaceutical
• Clinical Stage
• Rare Diseases
• Unmet Medical Needs
• Cardiovascular Therapies
• Strategic Pivot

IKT financial model: income statement, cash flow and balance sheet